EMA Authorised: Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) (levodopa;carbidopa;entacapone) — Orion Corporation

View source ↗

Summary

EU marketing authorisation granted for Corbilta, a fixed-dose combination of levodopa, carbidopa and entacapone, for Parkinson's disease, to Orion Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Corbilta (levodopa;carbidopa;entacapone)

Snippet

Status: Authorised. Therapeutic area: Parkinson Disease. MAH: Orion Corporation. Decision date: 02/06/2025